Most Recent Articles about Allergan plc.
Healthcare 16-24% Target Net Gains Pace WallStars For October Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
VistaGen: Expensive At 12x Its Book Value Per Share Oct 09, 2018 - VistaGen is a clinical-stage biopharmaceutical company developing treatments to fight depression and other central nervous system illnesses.With a large target market size and candidates at Phase 2 of
Allergan And Cenicriviroc In NASH Fibrosis: Revisiting FDA Guidelines For Conditional Approval Oct 03, 2018 - Allergan generates increasing revenues.Its NASH franchise is also progressing satisfactorily with the AURORA Phase 3 NASH trial interim data readout anticipated H1/2019.Clinically, cenicriviroc has sh

Related Companies

Name Exchange Price Mkt Cap
CELG Celgene Corporation NASDAQ $87.23 $61.35B
SHPG Shire plc NASDAQ $176.25 $46.08B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $175.8 $44.93B
ZTS Zoetis Inc. NYSE $88.3 $42.55B
REGN Regeneron Pharmaceuticals, Inc. NASDAQ $386.665 $41.78B
Sector: Health Care > Industry: Major Pharmaceuticals